Related Experiment Video
Updated: Jan 21, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer
Takefumi Komiya1, Regan M Memmott1, Gideon M Blumenthal1
1Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Background:
Single-agent pemetrexed is a treatment for recurrent non-squamous non-small cell lung cancer (NSCLC) that provides limited benefit. Preclinical studies showed promising synergistic effects when the mammalian target of rapamycin (mTOR) inhibitor sirolimus was added to pemetrexed.
Methods:
This was a single-institution phase I/II study of pemetrexed in combination with sirolimus. The primary endpoint for the phase I was to determine the maximum tolerated dose (MTD) and safety of the combination. The primary endpoint for the phase II portion was to determine the overall response rate at the MTD. Key eligibility criteria included recurrent, metastatic NSCLC, ECOG performance status of 0-2, and adequate organ function. Sirolimus was administered orally daily after an initial loading dose, and pemetrexed was given intravenously on day 1 of every 21-day cycle.
Results:
Forty-two patients with recurrent, metastatic NSCLC were enrolled, 22 in phase I and 20 in phase II. The MTD was pemetrexed 500 mg/m2 every 3 weeks, and sirolimus 10 mg on day 1, and 3 mg daily thereafter. Treatment-related adverse events (AEs) occurred in 38 (90.5%) patients. The most common grade 3-4 treatment-related AEs were lymphopenia (31%) and hypophosphatemia (19%). Two treatment-related deaths occurred due to febrile neutropenia and infection, respectively. Among 27 total patients treated at the MTD, 6 (22.2%) had a partial response (PR), 12 (44.4%) had stable disease (SD) and 5 (18.5%) had progressive disease. Median progression-free survival (PFS) was 18.4 weeks (95% CI: 7.0-29.4).
Conclusions:
The combination of pemetrexed and sirolimus is active in heavily-pretreated NSCLC (ClinicalTrials.gov Identifier: NCT00923273).
Insights
Adding sirolimus to pemetrexed shows activity in patients with non-small cell lung cancer (NSCLC). This combination therapy demonstrated a partial response rate of 22.2% in a phase I/II clinical trial.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Single-agent pemetrexed offers limited benefit for recurrent non-squamous non-small cell lung cancer (NSCLC).
- Preclinical data suggested synergistic effects between pemetrexed and the mTOR inhibitor sirolimus.
Purpose of the Study:
- To determine the maximum tolerated dose (MTD) and safety of the pemetrexed-sirolimus combination in NSCLC patients.
- To evaluate the overall response rate (ORR) of the combination therapy at the MTD.
Main Methods:
- A single-institution phase I/II clinical study was conducted.
- Patients received oral sirolimus daily and intravenous pemetrexed every 21 days.
- Eligibility criteria included recurrent, metastatic NSCLC and adequate organ function.
Main Results:
- The MTD was established as pemetrexed 500 mg/m² every 3 weeks with sirolimus 10 mg loading dose followed by 3 mg daily.
- Grade 3-4 adverse events included lymphopenia (31%) and hypophosphatemia (19%).
- Among 27 patients at MTD, 22.2% had partial response, 44.4% stable disease, and median progression-free survival was 18.4 weeks.
Conclusions:
- The combination of pemetrexed and sirolimus demonstrates activity in heavily pretreated NSCLC.
- This regimen warrants further investigation in non-squamous NSCLC treatment.
Related Concept Videos
Phase Diagrams
Lung Capacity
Phase Transitions
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Inductance: Single-Phase And Three-Phase Line
Single-Phase Two-Wire Line:
A single-phase line consists of two solid cylindrical conductors, denoted as x and y. Each conductor carries phasor currents ix and iy, respectively. Given that the sum of these currents is...
Capacitance: Single-Phase And Three-Phase Line
Single-Phase Lines
Consider a single-phase, two-wire transmission line with equal phase spacing energized by a voltage source. One conductor carries a uniform positive charge, while the other carries an equal negative charge. The capacitance C of the line can be derived from the voltage V between the conductors. For a one-meter section of the line, the capacitance is given...

